Xenon Pharmaceuticals Stock Forecast, Price & News

Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions

Is Xenon Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Xenon Pharmaceuticals stock.
View analyst ratings for Xenon Pharmaceuticals or view top-rated stocks.

How has Xenon Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Xenon Pharmaceuticals' stock was trading at $12.71 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, XENE stock has increased by 104.6% and is now trading at $26.00.
View which stocks have been most impacted by COVID-19.

Are investors shorting Xenon Pharmaceuticals?

Xenon Pharmaceuticals saw a increase in short interest in the month of December. As of December 15th, there was short interest totaling 2,120,000 shares, an increase of 26.2% from the November 30th total of 1,680,000 shares. Based on an average daily trading volume, of 2,190,000 shares, the days-to-cover ratio is presently 1.0 days.
View Xenon Pharmaceuticals' Short Interest.

When is Xenon Pharmaceuticals' next earnings date?

Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Xenon Pharmaceuticals.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) posted its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.44) by $0.08. The biopharmaceutical company had revenue of $8.12 million for the quarter, compared to analyst estimates of $7.76 million. Xenon Pharmaceuticals had a negative net margin of 328.86% and a negative trailing twelve-month return on equity of 28.30%. During the same quarter last year, the company earned ($0.25) EPS.
View Xenon Pharmaceuticals' earnings history.

What price target have analysts set for XENE?

5 Wall Street analysts have issued 1-year price objectives for Xenon Pharmaceuticals' shares. Their forecasts range from $40.00 to $48.00. On average, they expect Xenon Pharmaceuticals' stock price to reach $44.00 in the next year. This suggests a possible upside of 69.2% from the stock's current price.
View analysts' price targets for Xenon Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the following people:

• Ian C. Mortimer, President, Chief Executive Officer & Director
• Sherry Aulin, Chief Financial Officer
• Sheila M. Grant, Senior VP-Research & Development Operations
• Christopher Kenney, Chief Medical Officer
• Robin Sherrington, Executive Vice President-Strategy & Innovation

Who are some of Xenon Pharmaceuticals' key competitors?

Some companies that are related to Xenon Pharmaceuticals include Arrowhead Pharmaceuticals (ARWR), Perrigo (PRGO), HUTCHMED (HCM), Zai Lab (ZLAB), Ultragenyx Pharmaceutical (RARE), Ionis Pharmaceuticals (IONS), Blueprint Medicines (BPMC), Alkermes (ALKS), Galapagos (GLPG), Cerevel Therapeutics (CERE), Arvinas (ARVN), CureVac (CVAC), Intra-Cellular Therapies (ITCI), ACADIA Pharmaceuticals (ACAD) and Hypera (HYPMY).
View all of XENE's competitors.

What other stocks do shareholders of Xenon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI).

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.10%) and Cutler Group LP (0.00%). Company insiders that own Xenon Pharmaceuticals stock include Christopher John Kenney, Frank A Holler, Seggern Christopher Von, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends for Xenon Pharmaceuticals.

Which institutional investors are buying Xenon Pharmaceuticals stock?

XENE stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., and Cutler Group LP. Company insiders that have bought Xenon Pharmaceuticals stock in the last two years include Christopher John Kenney, and Seggern Christopher Von.
View insider buying and selling activity for Xenon Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $26.00.

How much money does Xenon Pharmaceuticals make?

Xenon Pharmaceuticals has a market capitalization of $1.34 billion and generates $32.17 million in revenue each year. The biopharmaceutical company earns $-28.84 million in net income (profit) each year or ($1.63) on an earnings per share basis.

How many employees does Xenon Pharmaceuticals have?

Xenon Pharmaceuticals employs 129 workers across the globe.

What is Xenon Pharmaceuticals' official website?

The official website for Xenon Pharmaceuticals is www.xenon-pharma.com.

Where are Xenon Pharmaceuticals' headquarters?

Xenon Pharmaceuticals is headquartered at 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at [email protected], or via fax at 604-484-3450.